

CANCER SCREENING FACT SHEET (3 PAGES)

DENMARK – CERVIX – 2017

SCREENING POLICY (2017)

- Population-based screening recommendation given by Danish Health Authority in 1986 but fully implemented in 2006.
- Current screening policy in force since 2012 and regions
- National target age range 23-64 years
- Age-eligible women with a cervix in situ are eligible but women with total hysterectomy for benign reasons are excluded. Women may also inform the region if they don't want to receive further invitations to screening.
- Interval between negative screens is three years for women aged 23-49 years and five years for women aged 50-64 years.
- The primary screening test is cytology for women aged 23-59 years with HPV as a triage test. HPV DNA test is primary screening test for women aged 60-64 years.
- Criteria for a follow-up cytology test is ASCUS for women under 30 years or LSIL (any age). Alternatively, triage with mRNA test can be used for these women.
- Criteria for referral for diagnostic confirmation is ASC-H, AGC, HSIL, AIS or any type of malignant cell. Women with a positive HPV triage test are also referred for colposcopy
- The screening program is currently under review by a working group under the Danish Health Authorities
- Before 2007 the recommendation was to offer cytology screening every third year to women aged 23-59 years

More information on the screening programme: Screening for Cervical Cancer – Recommendations [in Danish – with a summary in English]: <http://www.sst.dk/~media/B1211EAFEDFB47C5822E883205F99B79.ashx>

POPULATION, TESTS AND TEST COVERAGE (2015)

Data from Denmark is not yet available in NordScreen platform. The figures provided below are from national sources.

Summary measures [age range]

Total population in the national target age range [XX-XX]	1 533 453
Total population in the common core age range [30-59]*	1 110 412
Total number of tests registered [XX-XX]	387 000
Total number of tests within the national target age range [XX-XX]	NA
Total number of tests within the common core age range [30-59]*	NA
Test coverage according to national screening policy [3- or 5-yearly; 23-64]	75.1%** (2015)
5.5-yearly test coverage within the common core age range [30-59]*	NA



*The common core age range [30-59] is the minimum age group targeted in EU countries that have population-based screening policies in place.¹

**Dansk Kvalitetsdatabase for Livmoderhalskræftscreening. Årsrapport 2015

¹ Cancer Screening in the European Union (2017) Report on the implementation of the Council Recommendation on cancer screening. Available from https://ec.europa.eu/health/sites/health/files/major_chronic_diseases/docs/2017_cancerscreening_2ndreportimple mentation_en.pdf

CERVICAL CANCER BURDEN (2010-2014, FROM NORDCAN²)

Number of cervical cancers per year	376
Number of cervical cancer deaths per year	99
Age-standardised (W) incidence rate	10.2 / 100 000 person-years
Age-standardised (W) mortality rate	1.9 / 100 000 person-years



² Engholm G, Ferlay J, Christensen N, Kejs AMT, Hertzum-Larsen R, Johannesen TB, Khan S, Leinonen MK, Ólafsdóttir E, Petersen T, Schmidt LKH, Trykker H and Storm HH. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 7.3 (08.07.2016). Association of the Nordic Cancer Registries. Danish Cancer Society. Accessed on 14.12.2016. Available from <http://www.ancr.nu>